Tramadol

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, March 18, 2024
Research, Epilepsy, PO, Seizure, Partnership, Risk, Patient, Tramadol, Acquisition, American Epilepsy Society, GABAA, Enrollment, NRF1, SBMA, Schedule, Hydromorphone, Society, Therapy, DSM-IV codes, Safety, GAERS, Morphine, Pain, FDA, AES, Annual general meeting, Food, Pharmaceutical industry

MIAMI, March 18, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the year ended December 31, 2023.

Key Points: 
  • “We made considerable progress across our pipeline of differentiated neurologic therapies in 2023," said Alexandra MacLean, M.D., Chief Executive Officer of Avenue.
  • Pending additional financing, we look forward to progressing BAER-101 and IV tramadol for patients facing great unmet need.
  • R&D Expenses: Research and development expenses for the full year 2023 were $6.1 million, compared to $2.7 million in 2022.
  • G&A Expenses: General and administrative expenses for the full year 2023 were $4.2 million, compared to $5.3 million in 2022.

Kush: what is this dangerous new west African drug that supposedly contains human bones?

Retrieved on: 
Tuesday, January 16, 2024
Ageing, Methaqualone, Fentanyl, Legislation, Formaldehyde, HIV/AIDS, Joint, Euphoria, Rehabilitation, Relaxation, Consciousness, Walking, Unemployment, Income, Tramadol, Risk, Self-harm, Physical abuse, Public, Illegal drug trade, Heroin, Child, Morphine, Cannabis, Confusion, Internet, Tobacco, Somnolence, Poverty, Hallucination, Man, Drug

Another reason might be the drug content of the bones themselves, if the deceased was a fentanyl or tramadol user.

Key Points: 
  • Another reason might be the drug content of the bones themselves, if the deceased was a fentanyl or tramadol user.
  • The drug is reported in both Guinea and Liberia, which share porous land borders with Sierra Leone, making drug trafficking easy.
  • The danger of the drug is twofold: the risk of self-injury to the drug taker and the highly addictive nature of the drug itself.
  • The effectiveness of legislation alone is questionable, and many of those who attend the very limited rehabilitation centres return to drug use.

Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol

Retrieved on: 
Thursday, January 4, 2024
Patient, Schedule, Partnership, Food, Tramadol, Pain, FDA, Therapy, Clinical trial, Element, Hypoventilation, CRL, DSM-IV codes, Safety, Hydromorphone, Morphine, Pharmaceutical industry

The final non-inferiority study is designed to assess the theoretical risk of opioid-induced respiratory depression related to opioid stacking on IV tramadol compared to IV morphine.

Key Points: 
  • The final non-inferiority study is designed to assess the theoretical risk of opioid-induced respiratory depression related to opioid stacking on IV tramadol compared to IV morphine.
  • “We have worked collaboratively with the FDA over the last year to design a study that will address a theoretical safety risk.
  • The study will randomize approximately 300 post bunionectomy patients to IV tramadol or IV morphine for pain relief administered during a 48-hour post-operative period.
  • Of note, IV tramadol demonstrated safety and efficacy in this same surgical model in two Phase 3 efficacy trials.

Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, November 13, 2023
CNS, Annual general meeting, Safety, American Epilepsy Society, Food, SBMA, D, Therapy, NRF1, Data, Patient, Research, DSM-IV codes, U.S. FDA, Neurology, FDA, Hydromorphone, Pain, Seizure, Tramadol, Generalized tonic–clonic seizure, Morphine, PO, AES, Pharmaceutical industry, Video game, Avenue, MIAMI

MIAMI, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the third quarter ended September 30, 2023.

Key Points: 
  • “In the third quarter, Avenue continued to successfully execute across our pipeline of innovative CNS treatments," said Alexandra MacLean, M.D., Chief Executive Officer of Avenue.
  • Topline data for the Phase 1b/2a clinical trial of AJ201 in SBMA are expected in the second quarter of 2024.
  • R&D Expenses: Research and development expenses for the third quarter of 2023 were $0.9 million, compared to $0.2 million for the third quarter of 2022.
  • G&A Expenses: General and administrative expenses for the third quarter of 2023 were $1.2 million, compared to $0.5 million for the third quarter of 2022.

Intelligent Bio Solutions Inc. Reports Fiscal 2024 First Quarter Financial Results and Operational Highlights

Retrieved on: 
Wednesday, November 8, 2023
Auctus, FDA, Ketamine, Mining, Government, Acquisition, Aviation, Growth, Agriculture, Tramadol, ISO, Intelligence, Cryptocurrency, Pharmaceutical industry

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal first quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • First Quarter & Recent Highlights:
    Expanded into the New Zealand market, representing a significant milestone in the Company’s growth strategy for its Intelligent Fingerprinting Drug Screening System.
  • Enhanced customer portfolio with specialist container logistics firm VKVP Haulage adopting the Company’s Intelligent Fingerprinting Drug Screening System.
  • Additionally, existing customer Auctus Management Group completed 25,000 tests using the Company’s Intelligent Fingerprinting Drug Screening System.
  • First Fiscal Quarter Ended September 30, 2023, Financial Results
    All amounts are expressed in U.S. dollars unless indicated otherwise.

Intelligent Bio Solutions Completes Critical Development Milestone in Plans to Add Ketamine and Tramadol to Fingerprint Drug Test

Retrieved on: 
Friday, September 8, 2023
University, NYU, Ground substance, Home Office, Psychological abuse, National Drug and Alcohol Research Centre, Ketamine, Collection, Police, Engineering, Drug, National Drug Evidence Centre, Tramadol, Intelligence, Pharmaceutical industry

NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of a key development milestone in its plans to add ketamine and tramadol to its Intelligent Fingerprinting Drug Screening System.

Key Points: 
  • NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of a key development milestone in its plans to add ketamine and tramadol to its Intelligent Fingerprinting Drug Screening System.
  • After completing these activities and successful clinical trials, the assays can be added to the panel of substances detected by the Company’s proprietary drug screening system.
  • “While both ketamine and tramadol are widely used for legitimate medical and veterinary purposes, its increased use as a recreational drug has rapidly become a growing concern when it comes to workplace drug testing,” said Harry Simeonidis, President and CEO of Intelligent Bio Solutions.
  • It is non-invasive, fast, and cost-effective, with sample collection taking seconds and simultaneous screening for multiple drug groups in ten minutes.

Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference

Retrieved on: 
Tuesday, September 5, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ketan, Pharma, Naloxone, Oxycodone, Food and Drug Administration, Opioid use disorder, ADHD, DSM-IV codes, OUD, VAS, FQ, Physical dependence, II, Pain, Visual analogue scale, NOP, Patient, Risk, MOP, Neuropathic pain, Pain management, Addiction, Drug, HAP, FDA, Tramadol, Food, Pharmaceutical industry, Tris

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.

Key Points: 
  • Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.
  • The findings will be shared on Thursday, September 7, in a poster presentation at the 2023 PAINWeek conference in Las Vegas.
  • Study participants randomly received a single dose of placebo, cebranopadol 600 μg, cebranopadol 1000 μg, tramadol IR 600 mg or oxycodone IR 40 mg.
  • The difference between the good effects and bad effects of drugs have been linked to their abuse potential.

Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, August 10, 2023
Epilepsy, DSM-IV codes, Seizure, Spinal and bulbar muscular atrophy, IV, Symantec Endpoint Protection, PO, Anterior grey column, Schedule, SBMA, Pain, U.S. FDA, Morphine, Patient, Hydromorphone, Research, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tramadol, Food, Safety, Generalized tonic–clonic seizure, D, Pharmaceutical industry, Avenue

MIAMI, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the second quarter ended June 30, 2023.

Key Points: 
  • Additionally, we reported promising preclinical results for BAER-101 that show robust anti-seizure activity in a translational animal model of absence epilepsy.
  • R&D Expenses: Research and development expenses for the second quarter of 2023 were $3.0 million, compared to $0.2 million for the second quarter of 2022.
  • G&A Expenses: General and administrative expenses for the second quarter of 2023 were $0.9 million, compared to $0.5 million for the second quarter of 2022.
  • Net Loss: Net loss attributable to common stockholders for the second quarter of 2023 was $4.0 million, or $0.52 per share, compared to a net loss of $0.6 million, or $0.41 per share, for the second quarter of 2022.

Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol

Retrieved on: 
Tuesday, July 25, 2023
Epilepsy, DSM-IV codes, Partnership, IV, Element, Schedule, Pain, Morphine, Patient, Physician, Hypoventilation, Norepinephrine, Hydromorphone, Serotonin, FDA, Therapy, Tramadol, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Avenue

The agreed upon non-inferiority study is designed to assess the theoretical risk of opioid-induced respiratory depression related to opioid stacking on IV tramadol compared to IV morphine.

Key Points: 
  • The agreed upon non-inferiority study is designed to assess the theoretical risk of opioid-induced respiratory depression related to opioid stacking on IV tramadol compared to IV morphine.
  • The study will randomize post bunionectomy patients to IV tramadol or IV morphine for pain relief administered during a 48-hour post-operative period.
  • Of note, IV tramadol demonstrated safety and efficacy in this same surgical model in a Phase 3 efficacy trial.
  • We remain committed to Avenue’s mission of delivering impactful therapies to treat patients with neurologic diseases, while building shareholder value,” said Dr. MacLean.

Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Friday, May 12, 2023
Epilepsy, DSM-IV codes, IV, Symantec Endpoint Protection, Addiction, Tramadol, Type, SBMA, Food and Drug Administration Amendments Act of 2007, Panic, Patient, Division, Risk, Hypoventilation, Spinal and bulbar muscular atrophy, Neuro, FDA, Therapy, Research, Spinocerebellar ataxia, Food, Safety, D, Pharmaceutical industry, Cryptocurrency, Spine, Pain management, Avenue

MIAMI, May 12, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2023.

Key Points: 
  • MIAMI, May 12, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2023.
  • In addition, Jay Kranzler, M.D., Ph.D., a current Director of Avenue, was appointed as the Chairman of Avenue.
  • R&D Expenses: Research and development expenses for the first quarter of 2023 were $1.2 million, compared to $1.8 million for the first quarter of 2022.
  • G&A Expenses: General and administrative expenses for the first quarter of 2023 were $1.0 million, compared to $1.0 million for the first quarter of 2022.